Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProMetic Life Sciences' expanded partnership with Wuhan Institute of Biologic Products (WIBP) and its parent company CNBG has led to completion of the first set of milestones.
Subscribe to our email newsletter
One of the achievements includes successful scale up of the Plasma Protein Purification System (PPPSTM) manufacturing platform in CNBG’s Wuhan facility.
The new milestone demonstrates the robustness of PPPSTM process, besides the success of the ongoing technology transfer program.
The scale up process is believed to result in further cost reduction for Prometic’s own facility in Laval.
ProMetic CEO Pierre Laurin said CNBG, a large biotech company in China, is a major manufacturer of vaccines and blood products across the globe.
"Our recent achievement with them fulfills one of ProMetic’s long standing priorities for its technology," Laurin added.